PURPOSE: To describe pharmacologic variables correlated with the development of neurologic toxicity in patients treated with suramin. METHODS: Eighty-one patients were treated with suramin in a phase I study. The rate of drug infusion was continuously adjusted to maintain a preassigned plasma suramin concentration (175, 215, or 275 micrograms/mL) for a fixed duration (2 to 8 weeks). RESULTS: Eight patients developed grade III/IV neurologic motor impairment (predominantly motor axonal polyneuropathy). All were treated at the 275-micrograms/mL concentration. One patient treated at the 215-micrograms/mL concentration developed grade II motor dysfunction. In addition, seven of nine patients had sensory symptoms. Pharmacologic variables associated with the development of polyneuropathy included total cumulative suramin dose, duration of exposure to plasma concentrations greater than 200 micrograms/mL, and area under the curve (AUC) greater than 200 micrograms/mL. CONCLUSION: Significant neurologic toxicity can result from therapy with suramin, even when dosing is designed to avoid exposure to plasma concentrations greater than 350 micrograms/mL. Future clinical trials of suramin should be designed in such a way as to limit the total cumulative dose to < or = 157 mg/kg given over a period of > or = 8 weeks, limit the period of exposure to plasma suramin concentrations greater than 200 micrograms/mL to < or = 25 days, and limit the AUC greater than 200 micrograms/mL to < or = 48,000 mg.h/AL.
PURPOSE: To describe pharmacologic variables correlated with the development of neurologic toxicity in patients treated with suramin. METHODS: Eighty-one patients were treated with suramin in a phase I study. The rate of drug infusion was continuously adjusted to maintain a preassigned plasma suramin concentration (175, 215, or 275 micrograms/mL) for a fixed duration (2 to 8 weeks). RESULTS: Eight patients developed grade III/IV neurologic motor impairment (predominantly motor axonal polyneuropathy). All were treated at the 275-micrograms/mL concentration. One patient treated at the 215-micrograms/mL concentration developed grade II motor dysfunction. In addition, seven of nine patients had sensory symptoms. Pharmacologic variables associated with the development of polyneuropathy included total cumulative suramin dose, duration of exposure to plasma concentrations greater than 200 micrograms/mL, and area under the curve (AUC) greater than 200 micrograms/mL. CONCLUSION: Significant neurologic toxicity can result from therapy with suramin, even when dosing is designed to avoid exposure to plasma concentrations greater than 350 micrograms/mL. Future clinical trials of suramin should be designed in such a way as to limit the total cumulative dose to < or = 157 mg/kg given over a period of > or = 8 weeks, limit the period of exposure to plasma suramin concentrations greater than 200 micrograms/mL to < or = 25 days, and limit the AUC greater than 200 micrograms/mL to < or = 48,000 mg.h/AL.
Authors: Saby George; Robert Dreicer; Jessie J L Au; Tong Shen; Brian I Rini; Susan Roman; Matthew M Cooney; Tarek Mekhail; Paul Elson; Guillaume M Wientjes; Ram Ganapathi; Ronald M Bukowski Journal: Clin Genitourin Cancer Date: 2008-09 Impact factor: 2.872
Authors: Daryl C Drummond; Charles O Noble; Zexiong Guo; Mark E Hayes; John W Park; Ching-Ju Ou; Yun-Long Tseng; Keelung Hong; Dmitri B Kirpotin Journal: J Pharmacol Exp Ther Date: 2008-10-23 Impact factor: 4.030
Authors: M A Villalona-Calero; G A Otterson; M G Wientjes; F Weber; T Bekaii-Saab; D Young; A J Murgo; R Jensen; T-K Yeh; Y Wei; Y Zhang; C Eng; M Grever; J L-S Au Journal: Ann Oncol Date: 2008-07-15 Impact factor: 32.976
Authors: David von der Ahe; Petra Huehnchen; Mustafa Balkaya; Sarah Peruzzaro; Matthias Endres; Wolfgang Boehmerle Journal: Molecules Date: 2018-02-07 Impact factor: 4.411